A large number of experts experienced in the treatment of rheumatoid arthritis were involved in formulating a consensus statement on the use of B cell-targeted treatment with rituximab in patients with rheumatoid arthritis. The statement was supported by data from randomised controlled clinical trials and the substantial literature on oncology. The statement underwent three rounds of discussions until its ultimate formulation. It should guide clinicians in the use of this newly approved biological agent in treating patients with rheumatoid arthritis.
- ACR, American College of Rheumatology
- SCDAI, Simplified composite Disease Activity Index
- DAS28, 28-joint Disease Activity Score
- DMARD, disease-modifying antirheumatic drug
- HACA, human antichimeric antibody
- MTX, methotrexate
- SDAI, simplified Disease Activity Index
- TNF, tumour necrosis factor
Statistics from Altmetric.com
Published Online First 20 December 2006
Competing interests: The views expressed in this guidance document including the final recommendations were not influenced by the sponsor and no representative of the sponsor was present in any of the discussion sessions. However, the guidance document was developed with the help of an unrestricted educational grant and all participants except the patient representative have been active on advisory boards or participated in clinical trials by the sponsor.
Members of the Working Group on the Rituximab Consensus Statement: Jordi Carbonell, Bernard Combe, Maurizio Cutolo, Thomas Dörner, Angela Gause, Juan Gomez-Reino, Carlos Gonzales Fernandes, John D Isaacs, José Luis Marenco, Xavier Mariette, Marco Matucci-Cerinic, Carlo-Maurizio Montecucco, Hubert Nüßlein, Mikkel Østergaard, Eliseo Pascual, Piet van Riel, Andrea Rubbert, Raimon Sanmarti, Zoltan Sekanecz, Paul-Peter Tak, Hans-Peter Tony, Gabriele Valentini, Guido Valesini.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.